Product
Cangrelor
Aliases
Kengreal
Name
KENGREAL
INN Name
cangrelor
FDA Approved
Yes
9 clinical trials
1 organization
10 indications
1 document
Indication
Acute IschemiaIndication
Coronary Artery DiseaseIndication
Acute Coronary SyndromeIndication
Myocardial InfarctionIndication
Cardiogenic ShockIndication
ST-elevation myocardial infarctionIndication
AngioplastyClinical trial
A Prospective, Open-Label, Single-Arm, Multi-Center Study To Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) And Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of ThrombosisStatus: Completed, Estimated PCD: 2019-08-31
Clinical trial
REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (REPERFUSE)Status: Recruiting, Estimated PCD: 2026-06-02
Clinical trial
Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary InterventionStatus: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Comparison of Pharmacodynamic Effects of Tirofiban vs. Cangrelor in N-STEMI Patients Undergoing Percutaneous Coronary InterventionStatus: Terminated, Estimated PCD: 2019-06-27
Clinical trial
Pharmacodynamic and Pharmacokinetic Profiles on Switching From Cangrelor to Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet -6 (SWAP-6) StudyStatus: Completed, Estimated PCD: 2023-02-02
Clinical trial
Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic ShockStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Evaluation of Myocardial Reperfusion and Residual Thrombotic Burden After Primary PCI for STEMI in Patients With High on Ticagrelor Platelet Reactivity Treated by IV Cangrelor Versus Ticagrelor AloneStatus: Completed, Estimated PCD: 2023-03-31
Clinical trial
PharmacOdynaMic Effects of Cangrelor in PatiEnts wIth Acute or chronIc Coronary Syndrome Undergoing Percutaneous Coronary Intervention (POMPEII Registry)Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Pharmacodynamic and Pharmacokinetic Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment: The Switching Antiplatelet -5 (SWAP-5) StudyStatus: Completed, Estimated PCD: 2021-08-16
Document
DailyMed Label: KENGREALOrganization
Chiesi USA, Inc.